ELISA Analyzers Market - By Type (Optical Filter Analyzers, Optical Grating Analyzers), Mode (Automated, Semi-Automated), Modality (Stand-alone), Application (Immunology, Vaccine Development), End-use (CROs, Diagnostic Laboratories) – Global Forecast (2024 - 2032)

ELISA Analyzers Market Size

ELISA Analyzers Market size was valued at around USD 587.1 million in 2023 and is estimated to grow at 4.2% CAGR from 2024 to 2032. ELISA analyzer is a sophisticated laboratory instrument used to automate and streamline the process of conducting enzyme-linked immunosorbent assays (ELISA). It is a common technique in immunology used to detect the presence of specific antibodies or antigens in a sample.
 

Chronic diseases such as cancer, cardiovascular diseases, and autoimmune disorders, along with infectious diseases like HIV/AIDS, hepatitis, and COVID-19, are on the rise globally. For instance, the World Health Organization (WHO) forecasts a significant surge in new cancer cases by 2050, with projections indicating over 35 million new cases. This represents a substantial 77% increase compared to the estimated 20 million cases recorded in 2022. This escalating disease burden necessitates efficient and accurate diagnostic methods to detect and monitor these conditions. ELISA analyzers play a crucial role in diagnosing and monitoring such diseases by detecting specific antibodies or antigens in patient samples.
 

Furthermore, technological advancements in diagnostic testing have greatly enhanced the accuracy and sensitivity of ELISA assays. These improvements enable healthcare professionals to detect diseases at an early stage, facilitating timely intervention and improving patient outcomes. ELISA analyzers offer precise and reliable results, making them indispensable tools in clinical laboratories and healthcare settings.
 

ELISA Analyzers Market Trends

• With the increasing demand for point of care testing, which is estimated to reach 78.3 billion by 2032, and automation in laboratory workflows, there's a growing preference for portable and automated ELISA analyzers.
   
• Portable ELISA analyzers allow for on-site testing in remote or resource-limited settings, enabling rapid diagnosis and timely treatment initiation. Moreover, automated ELISA systems streamline laboratory operations, reducing manual errors, and increasing testing throughput. This enhances efficiency and productivity in healthcare facilities, driving the adoption of ELISA analyzer.
   

ELISA Analyzers Market Analysis

Based on type, the market is divided into optical filter ELISA analyzers and optical grating ELISA analyzers. The optical filter analyzers segment of the market is forecasted to reach USD 581.2 million by 2032, displaying robust growth propelled by several key factors.
 

• Optical filter ELISA analyzers are indispensable in in-vitro diagnostics and research due to their exceptional sensitivity and specificity in detecting analytes. Their precision in identifying and quantifying target molecules boosts diagnostic accuracy, driving adoption by healthcare professionals and researchers.
   
• In the pharmaceutical and biotechnology sectors, these analyzers play a crucial role in drug discovery, development, and validation processes. They enable high-throughput screening of drug candidates, biomarker discovery, and pharmacokinetic studies, accelerating the drug development timeline. With the growing demand for novel therapeutics, the adoption of ELISA analyzers is expected to surge, fueling market growth.
   

Based on mode, the ELISA analyzers market is bifurcated into automated ELISA analyzers and semi-automated ELISA analyzers. The automated ELISA analyzers segment accounted for USD 352.9 million in 2023.
 

• This growth can be attributed to the inherent advantages of automation in streamlining the ELISA process, reducing manual intervention, and enhancing reproducibility and reliability of results.
   
• The demand for high-throughput analysis across clinical, pharmaceutical, and research settings further propelled the adoption of automated systems, which excel in handling large volumes of samples with rapid turnaround time.
   
• Integration of advanced technologies and adherence to regulatory standards further bolstered the appeal of automated ELISA analyzers, ensuring standardized protocols and quality outcomes.
   
• Thus, this trend underscores the increasing importance of efficiency, scalability, and reliability in diagnostic testing, positioning automated platforms as integral tools in addressing evolving healthcare needs.
   

Based on modality, the ELISA analyzers market is divided into bench-top and stand-alone. The bench-top segment of the market is forecasted to reach USD 553.6 million by 2032, displaying robust growth propelled by several key factors.
 

• Continuous advancements in bench-top ELISA analyzer technology have improved their efficiency, accuracy, and user-friendliness, making them attractive to healthcare facilities, research labs, and diagnostic centers.
   
• These analyzers offer a cost-effective solution compared to stand-alone systems, with lower initial investment and maintenance costs, appealing to smaller facilities with limited budgets.
   
• Their compact size allows easy integration into existing lab setups without significant restructuring, making them ideal for spaces with limited availability. Additionally, their versatility in performing a wide range of ELISA assays across various medical specialties enhances their appeal as multipurpose diagnostic tools.
   

Based on application, the ELISA analyzers market is bifurcated into immunology, vaccine development, drug monitoring & pharmaceutical industry, and other applications. The immunology segment accounted for USD 227.6 million in 2023.
 

• The rising prevalence of immunological disorders, advancements in research, significant funding from governments and health organizations, and the crucial role of ELISA analyzers in clinical diagnostics all contribute to this growth.
   
• Technological advancements, extensive immunization programs, and the increased focus on immune responses due to the COVID-19 pandemic have further bolstered the demand for ELISA analyzers in immunology, ensuring sustained and expanding market presence.
   

Based on end-use, the ELISA analyzers market is bifurcated into biotechnology companies, pharmaceutical companies, contract research organizations (CROs), diagnostic laboratories, and other end-users. The diagnostic laboratories segment accounted for USD 227.7 million in 2023.
 

• Diagnostic laboratories have seen a surge in demand for testing due to the rise in chronic diseases like diabetes, cancer, and cardiovascular disorders. ELISA analyzers, essential for their high sensitivity and specificity in detecting biomarkers, became even more critical during the COVID-19 pandemic for serological testing.
   
• The pandemic heightened the need for these diagnostic tools, enhancing their market share. Additionally, the expansion and upgrading of healthcare infrastructure in many regions have further stimulated the adoption of ELISA analyzers in diagnostic laboratories.
   

The U.S. ELISA analyzers market is forecasted to reach USD 305.2 million by 2032.
 

• The aging population in the U.S. is more susceptible to chronic diseases and requires regular diagnostic testing, which propels the demand for reliable and efficient ELISA analyzers. For instance, according to the population reference bureau, the number of individuals aged 65 and older in the U.S. is expected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, the proportion of this age group within the total population is projected to grow from 17% to 23%.
   

The ELISA analyzers market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• Chronic ailments like cancer, HIV/AIDS, and autoimmune disorders are witnessing an upward trend in the UK. For instance, Macmillan cancer support forecasts that the number of individuals living with cancer in the UK currently surpasses 3 million. This number is predicted to rise to 3.5 million by 2025, 4 million by 2030, and further increase to 5.3 million by 2040. Thus, the necessity for ELISA analyzers as crucial instruments for diagnosing and monitoring these ailments is escalating, thereby driving the demand for such diagnostic equipment.
   

Japan ELISA analyzers market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan has a robust pharmaceutical and biotechnology sector, constantly engaged in research and development activities. ELISA analyzers are essential tools in drug discovery, development, and quality control processes, thereby stimulating demand from these industries.
   

The ELISA analyzers market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The Saudi Arabian government has been focusing on improving healthcare accessibility and quality through initiatives such as Vision 2030. Such initiatives often include investments in healthcare infrastructure, research, and development, which could boost the adoption of advanced diagnostic technologies like ELISA analyzers.
   

ELISA Analyzers Market Share

The ELISA analyzers sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
 

ELISA Analyzers Market Companies

Some of the eminent market participants operating in the ELISA analyzers industry include:

• Abbott Laboratories
• Agilent Technologies, Inc.
• bioMérieux S.A.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• DYNEX Technologies
• Erba Mannheim
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• PerkinElmer, Inc.
• Randox Laboratories Ltd.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Tecan Group Ltd.
• Thermo Fisher Scientific Inc.
   

ELISA Analyzers Industry News:

• In November 2023, DYNEX Technologies, has introduced the Agility Integra, a cutting-edge fully automated ELISA system. This innovative high-throughput system delivers enhanced speed, precision, and flexibility, specifically catering to the pharmaceutical and biotechnology sectors. With advanced software capabilities, it ensures robust results that adhere to FDA Regulation 21 CFR Part 11. This product launch strengthened the company’s product portfolio and gave it a competitive advantage in the market.
   

The ELISA analyzers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Optical filter ELISA analyzers
• Optical grating ELISA analyzers

Market, By Mode

• Automated ELISA analyzers
• Semi-automated ELISA analyzers

Market, By Modality

• Bench-top
• Stand-alone

Market, By Application

• Immunology
• Vaccine development
• Drug monitoring & pharmaceutical industry
• Other applications

Market, By End-use

• Biotechnology companies
• Pharmaceutical companies
• Contract research organizations (CROs)
• Diagnostic laboratories
• Other end-users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific 
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa